Arrowhead Pharma - ARWR STOCK NEWS

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced the approval of inducement grants for 21 new employees by its Board of Directors on April 3, 2025. The grants, approved under NASDAQ Listing Rule 5635(c)(4), collectively provide up to 34,190 restricted stock units to the new hires. These equity awards are structured outside the company's stockholder-approved equity incentive plans and feature a four-year annual vesting schedule.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced topline results from Part 2 of its Phase 1/2 study of ARO-C3, an RNAi therapeutic targeting complement component 3 (C3) for complement-mediated diseases. The study focused on patients with IgA nephropathy (IgAN).

Key findings from the trial (n=14) include:

• Mean sustained C3 reduction >87% through week 24
• Mean sustained AH50 reduction >76% through week 24
• Mean sustained Wieslab AP reduction >89% through week 24
• Mean reduction in spot UPCR of 41% by week 24, with maximum individual reduction of 89%

The treatment was generally well-tolerated with no serious adverse events reported. The most common side effects were headache, cough, and nasopharyngitis. The duration of effect supports quarterly or less frequent subcutaneous dosing in future studies. Additional results will be presented at a medical meeting in 2025.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented preclinical data for two first-in-class RNAi-based therapeutics for obesity treatment: ARO-INHBE and ARO-ALK7. Both candidates target fat storage pathways while potentially preserving lean muscle mass better than current obesity therapies.

Key preclinical results showed:

• ARO-INHBE achieved 19% body weight reduction and 22% fat mass reduction in mice
• ARO-ALK7 demonstrated 39% body weight reduction and 50% fat mass reduction
• Both treatments improved liver fat accumulation
• Combination with tirzepatide showed enhanced benefits

Phase 1/2 clinical trials are underway, with ARO-INHBE dosing initiated in December 2024 and initial data expected by end of 2025. ARO-ALK7 dosing is anticipated to begin in Q2 2025, with preliminary data expected by year-end 2025.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has expanded its 'We'll Get There Soon' campaign on Rare Disease Day with new patient-centric resources for Familial Chylomicronemia Syndrome (FCS). The initiative includes the launch of www.LowerMyTGs.com, a dedicated educational website, and the release of the 'Spotlight on FCS' white paper.

FCS is an ultra-rare genetic disorder affecting 1-13 people per million globally, impairing the body's ability to process triglycerides. Patients typically experience dangerously high triglyceride levels exceeding 880 mg/dL, increasing the risk of acute pancreatitis. Expert guidelines recommend maintaining levels below 500 mg/dL.

The new resources, developed in collaboration with the FCS Foundation, Action FCS, and FH Europe Foundation, provide educational content, patient testimonials, and community connection opportunities. The initiative aims to amplify patient voices and address the underdiagnosis of FCS while supporting those affected by extremely high triglycerides.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented preclinical data on ARO-ALK7, its investigational RNAi therapeutic targeting ALK7 for obesity treatment, at the Keystone Symposia on Obesity and Adipose Tissue in February 2025. The company received regulatory clearance to begin a Phase 1/2a clinical trial in New Zealand, with dosing expected in Q2 2025.

Preclinical studies showed dose-dependent reductions in ALK7 mRNA in adipose tissue, with approximately 80% knockdown at 0.3 mg/kg and 91% at 1.5 mg/kg in non-human primates. In diet-induced obese mice, ARO-ALK7 suppressed body weight gain by 40% and reduced fat mass by approximately 50% while preserving lean mass.

Notably, when combined with tirzepatide (a GLP-1/GIP receptor co-agonist), ARO-ALK7 showed additive effects on weight and fat loss while ameliorating tirzepatide's lean mass reduction. The fat loss mechanism involves increased energy expenditure and lipolysis without affecting food intake. Toxicology studies in rats showed the treatment was generally well-tolerated.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal 2025 first quarter results, highlighting significant developments. The company secured a major licensing agreement with Sarepta Therapeutics, receiving $825 million upfront ($500M cash, $325M equity investment) plus $250 million over five years, with potential additional payments of $300 million and approximately $10 billion in milestones.

The FDA accepted Arrowhead's NDA for plozasiran for familial chylomicronemia syndrome treatment, with a PDUFA date of November 18, 2025. Phase 3 PALISADE study showed positive results with significant reductions in triglycerides.

Financial results showed revenue of $2.5 million, down from $3.55 million year-over-year. Net loss widened to $173.1 million ($1.39 per share) compared to $132.9 million ($1.24 per share) in the previous year. Total cash resources stood at $552.9 million as of December 31, 2024.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has completed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). The deal includes a $500 million upfront payment and $325 million through Sarepta's purchase of Arrowhead stock at $27.25 per share. Additionally, Arrowhead will receive $250 million in annual $50 million installments over 5 years.

The agreement covers multiple clinical-stage programs including ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-DM1 for myotonic dystrophy, ARO-MMP7 for idiopathic pulmonary fibrosis, and ARO-ATXN2 for spinocerebellar ataxia 2. Three preclinical programs are also included. Arrowhead can earn up to $300 million in near-term payments for ARO-DM1 study enrollment, plus development milestones of $110-410 million and sales milestones of $500-700 million per program, along with tiered royalties up to low double digits.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced a webcast and conference call scheduled for February 10, 2025, at 4:30 p.m. ET. During this event, the company will discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024.

Investors can access the live audio webcast through the Events and Presentations page in the Investors section of Arrowhead's website. A replay will be available approximately two hours after the call concludes. Analysts wishing to participate in the conference call must register through the provided link to receive dial-in information and a personalized PIN code.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced FDA acceptance of its New Drug Application (NDA) for plozasiran, targeting familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA set a PDUFA date of November 18, 2025, with no advisory committee meeting currently planned.

The NDA is supported by positive Phase 3 PALISADE study results, which met its primary endpoint and key secondary endpoints. The study demonstrated that plozasiran achieved an 80% median reduction in triglycerides at the 25mg dose and an 83% reduction in acute pancreatitis risk compared to placebo. The most common side effects included abdominal pain, COVID-19, nasopharyngitis, and nausea.

Arrowhead plans to submit additional regulatory applications for plozasiran FCS treatment in 2025 and is preparing for commercial launch pending FDA approval.